ACTA NEUROPHARMACOLOGICA ›› 2022, Vol. 12 ›› Issue (6): 8-15.DOI: 10.3969/j.issn.2095-1396.2022.06.002

Previous Articles     Next Articles

Meta-Analysis of the Clinical Efficacy of Edaravone in the Treatment of Ischaemic Stroke

WANG Li-fei,LI Shu-rui   

  1. 1. Graduate School of Hebei North University,Zhangjiakou,075000,China  2. Department of Geriatrics,Handan Central Hospital,Handan,056000,China
  • Online:2022-12-26 Published:2023-08-30

Abstract:

Objective:To systematically evaluate the therapeutic effect of Edaravone on ischemic stroke. Methods:A computer search was conducted in Cochrane Library,Pubmed, Embase,ClinicalTrials,China knowledge Network database,Wanfang database and VIP periodical resource database. The years were set for each database to be built until December 2022. The literatures about randomized controlled trials and clinical trials of Edaravone in the treatment of ischemic stroke were selected,and the Cochrane risk assessment form was used to evaluate the quality of the retrieved literature. The experimental data related to research were extracted by Revman5.4 software and analyzed by Meta. Results:A total of 28 clinical trials were included. Meta-analysis showed that NIHSS score [MD=-3.85,95% CI(-4.94,-2.77)] and ADL score [MD=13.37,95%CI(11.05,15.69)] in the treatment of ischemic stroke with Edaravone. The improvement of related indexes was better than that of conventional treatment. Conclusion: The clinical efficacy of Edaravone in the treatment of ischemic stroke is better than that of conventional treatment,but high-quality clinical studies are still needed for further evidence.

Key words: edaravone, clinical efficacy, ischemic stroke, meta analysis